Loading organizations...
Key people at Eisana Corp.
Based in The Woodlands, Texas, Eisana Corp develops specialized medical devices designed to prevent chemotherapy-induced peripheral neuropathy through a non-invasive cooling system for the hands and feet. The oncology-focused company currently targets a domestic market of approximately 680,000 annual patients who are at high risk of developing permanent nerve damage from common cancer treatments. Operating with a dedicated team of three employees, the early-stage firm finances its ongoing research and product development through grants and contracts from the National Cancer Institute, the American Cancer Society, and the National Institutes of Health. In late 2023, the enterprise successfully secured a Phase 1 Small Business Innovation Research contract and was prominently featured in Project W for its technological solutions supporting cancer survivors. Eisana Corp was officially founded in 2020 by chief executive officer Dr. Carole Spangler Vaughn.
Eisana Corp (also known as Eisana Health) is an early-stage medical device company developing oncology solutions to prevent and treat side effects of cancer treatment, such as chemotherapy-induced peripheral neuropathy (CIPN) and hair loss.[1][2][3][4][5] Founded in 2020 and based in The Woodlands/Spring, Texas, it serves cancer patients by providing electrical stimulation devices that improve quality of life and aim to reduce healthcare costs associated with treatment side effects.[1][3][4] With 4 employees and $660,000 in funding raised, the company focuses on a platform for multiple products in this niche, showing early traction through SBIR involvement and a dedicated leadership team.[1][2]
Eisana Corp was founded in 2020 in The Woodlands, Texas, by Dr. Carole Spangler Vaughn, who serves as CEO, founder, inventor, and director.[1][4][5] Vaughn, holding a Ph.D. in Biophysics from Johns Hopkins University and an MBA from the University of Washington, brings over 25 years of experience in biopharma, business development, and medical ventures, including roles at Bristol-Myers Squibb, Dendreon Corporation, and as owner of MediVet Hawaii.[4] The idea emerged from her expertise in addressing cancer treatment side effects, particularly CIPN, as highlighted in CEO discussions on the company's site.[5] Early traction includes securing $660K in funding and building a small team, with pivotal hires like VP of Product Development Jessica Urban (25+ years in medical devices) and experienced executives in product management and finance.[1][4]
Eisana rides the wave of precision oncology and medtech innovation, where advances in electrical stimulation (e.g., neuromodulation) address unmet needs in cancer supportive care amid rising chemotherapy use.[1][5] Timing aligns with growing CIPN prevalence—affects up to 60% of patients—and demand for non-pharmacological solutions, fueled by post-pandemic healthcare cost pressures and aging populations.[1][3] Market forces like SBIR funding and regulatory tailwinds for devices favor nimble startups, positioning Eisana to influence the $10B+ oncology supportive care ecosystem by pioneering accessible, patient-centric tech that complements immuno-oncologies.[2][4]
Eisana's path forward hinges on clinical validation, FDA clearance for lead devices, and scaling its platform amid oncology medtech funding resurgence.[1][4] Trends like AI-enhanced neuromodulation and personalized cancer care will amplify its momentum, potentially expanding to more side effects or global markets. As it grows from $660K funding, expect partnerships with big pharma (leveraging Vaughn's network) to evolve its influence, transforming patient post-treatment experiences from survival to thriving—echoing its core mission since 2020.[1][4][5]
Key people at Eisana Corp.
